

Marfan Syndrome

Indications for Ordering

- Confirm diagnosis for individuals with suspected Marfan syndrome (MFS)
- Determine the specific *FBN1* gene variant in known affected individual
- Determine disease status in children or other at-risk family members of affected individuals

Test Description

- Sequencing
 - Polymerase chain reaction followed by bidirectional sequencing of *FBN1* coding regions and intron/exon boundaries
- Deletion/duplication analysis
 - Multiplex ligation-dependent probe amplification

Tests to Consider

Primary tests

[Marfan Syndrome \(*FBN1*\) Sequencing and Deletion/Duplication 2005584](#)

- Preferred test to confirm diagnosis when MFS is strongly suspected by consensus criteria

[Marfan Syndrome, *FBN1* Sequencing 2005589](#)

- Acceptable test to confirm diagnosis for individuals with clinical phenotype of MFS

Related tests

[Aortopathy Panel, Sequencing and Deletion/Duplication, 21 Genes 2006540](#)

- Preferred panel for individuals with clinical phenotype of aortic or vascular aneurysm, dissection, or rupture if no single specific diagnosis is strongly suspected

[Familial Mutation, Targeted Sequencing 2001961](#)

- Useful when a pathogenic familial variant identifiable by sequencing is known

Disease Overview

Prevalence – 1/5,000-10,000

Symptoms

- MFS is a connective tissue disorder
- A clinical diagnosis of MFS in an individual **without a family history** of MFS (Shprintzen-Goldberg syndrome [SGS], Loeys-Dietz syndrome [LDS], and Ehlers-Danlos syndrome type IV [EDS IV] have been excluded) is based on the presence of any of the following
 - Aortic root dilatation or dissection and ectopia lentis
 - Aortic root dilatation or dissection and pathogenic *FBN1* variant
 - Ectopia lentis and an *FBN1* gene variant previously reported to be associated with cardiovascular disease
 - Aortic root dilatation or dissection and at least 7 points from the table below

Revised Ghent Nosology (Loeys, 2010) Point Values for Specific Characteristics	
Characteristics	Point Value
Wrist AND thumb sign	3
Wrist OR thumb sign	1
Pectus carinatum	2
Pectus excavatum or chest asymmetry	1
Hindfoot deformity	2
Plain des planus	1
Pneumothorax	2
Dural ectasia	2
Acetabular protrusion	2
Reduced upper segment-to-lower segment (US/LS) ratio AND increased arm span-to-height ratio AND no severe scoliosis	1
Scoliosis or thoracolumbar kyphosis	1
Reduced elbow extension	1
Skin striae	1
Myopia >3 diopters	1
Mitral valve prolapse (all types)	1
Characteristic facial features	1
Score ≥7 indicates systemic involvement	

- A clinical diagnosis of MFS in an individual **with a family history** of MFS (SGS, LDS, and EDS IV have been excluded) is based on the presence of any of the following
 - Ectopia lentis
 - Systemic findings scoring 7 points or higher (refer to table of point values, above)
 - Aortic root dilation or dissection

- Other disorders associated with *FBN1* gene variants
 - Neonatal MFS – atrioventricular valve dysfunction, pulmonary emphysema, joint contractures, crumpled ears, and loose skin
 - MFS phenotype with severe congenital lipodystrophy and progeroid-like appearance
 - Mitral valve prolapse syndrome – mitral valve prolapse, pectus excavatum, scoliosis, mild arachnodactyly
 - Familial ectopia lentis – bilateral ectopia lentis, sometimes scoliosis
 - MASS syndrome – mitral valve prolapse, aortic enlargement, skin, skeletal findings
 - Weill-Marchesani syndrome type 2 – ectopia lentis, brachydactyly, joint stiffness, short stature
 - SGS – craniosynostosis, arachnodactyly, brachycephaly, pectus deformities, scoliosis, mental retardation, rarely aortic root dilatation
 - Aortic aneurysm, ascending and dissection
 - Acromicric dysplasia
 - Geleophysic dysplasia type 2
 - Stiff skin syndrome

Treatment issues

Early diagnosis is crucial for treatment of skeletal, orthopedic, and cardiovascular abnormalities

Genetics

Gene – *FBN1*

Inheritance – autosomal dominant

Penetrance – high variability; age dependent

De novo variants– 25% of cases

- Nonsense
- In- or out-of-frame deletions/insertions
- Splice-site variants
- Missense variants
 - Involve cysteine residues
 - Affect epidermal growth factor-like consensus sequences absent in 400 ethnically matched controls

Pathogenic variants

- The revised Ghent nosology defines causal *FBN1* variants
- Variants segregate with disease in MFS families
- Few genotype/phenotype correlations
- MFS with *FBN1* variants identified in exons 24-32 generally have a severe prognosis
- Exon 64 frameshift variants reported in individuals with Marfan phenotype, generalized lipodystrophy, and progeroid facial appearance
- Large genomic deletions of regulatory elements have been reported in individuals with MFS or MFS spectrum disorders, including MASS phenotype

Test Interpretation

Sensitivity/specificity

- Clinical sensitivity
 - Sequencing – ranges from 70-93%; dependent on accuracy of clinical diagnosis (Dietz, 2017; Korkko, 2002)
 - Deletion/duplication analysis – unknown
- Analytical sensitivity/specificity – 99%

Results

- Positive – known pathogenic *FBN1* variant detected
 - Individual predicted to be affected with MFS or *FBN1*-related disorder in a symptomatic individual
- Negative – no known pathogenic *FBN1* variant detected
 - Reduces risk, but does not exclude the diagnosis of MFS
- Inconclusive – variant of uncertain clinical significance may be detected

Limitations

- Not determined or evaluated
 - Deep intronic pathogenic variants
 - Regulatory region pathogenic variants
 - Large deletions/duplications of exon 40 may or may not be detected, depending on the location of breakpoints
 - Breakpoints of large *FBN1* deletions/duplications
- Variants in genes other than *FBN1* Diagnostic errors can occur due to rare sequence variations
- Do not use for prenatal testing for an unknown *FBN1* variant

References

- Dietz HC. Marfan Syndrome. 2001 Apr 18 [Updated 2017 Feb 2]. In: Pagon RA, Adam MP, Ardinger HH, et al., editors. GeneReviews [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2017. (www.ncbi.nlm.nih.gov/books/NBK1335/)
- Korkko J, et al. Sensitivity of conformation sensitive gel electrophoresis in detecting mutations in Marfan syndrome and related conditions. *J Med Genet.* 2002;39:34-41.
- Kumar A, Agarwal S. Marfan syndrome: An eyesight of syndrome. *Meta Gene.* 2014;2:96-105.
- Loeys BL, Dietz HC, et al. The revised Ghent nosology for the Marfan syndrome. *J Med Genet.* 2010;47:476-485